Endocyte Inc.

Endocyte Inc. of West Lafayette, Ind., has initiated a randomized Phase II clinical study of its EC145 drug in women with platinum-resistant ovarian cancer. In addition to the drug, patients will be treated with the company’s EC20 molecular imaging agent, which enables clinicians to identify tumors that overexpress folate receptors.





LATEST NEWS

• Headwall Taps Jim Gareau to Lead Optical Components and Assemblies Unit
  May 2, 2024
• Cognex Names Former Siemens VP Dennis Fehr CFO
  May 2, 2024
• 3D Holography Integrated Glasses Could Unlock Mixed Reality
  May 2, 2024
• Generative AI Achieves Superresolution with Minimal Tuning
  May 2, 2024
• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024